Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder
Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if a drug called topiramate is safe and effective
as an add-on therapy in the treatment of Obsessive-Compulsive Disorder (OCD). Topiramate is
an investigational drug for OCD, which means it has not been approved by the U.S. Food and
Drug Administration (FDA). Topiramate has been approved as an add-on therapy for adults and
children with partial onset seizures or generalized tonic-clonic seizures, and for patients 2
years of age and older with a severe form of epilepsy called Lennox-Gastaut Syndrome.
Up to 96 subjects will be enrolled in this study. This study consists of three phases:
Washout/Screening Phase, Double-Blind Phase, and Taper Phase. The total expected length of
your participation in the study is approximately four months.